An automated method for the measurement of a range of tyrosine kinase inhibitors in human plasma or serum using turbulent flow liquid chromatography–tandem mass spectrometry

Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS

(2011) Stéphane Bouchet et al.   CLINICA CHIMICA ACTA

Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors

(2011) Matthias Scheffler et al.   CLINICAL PHARMACOKINETICS

Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors

(2011) Paola Di Gion et al.   CLINICAL PHARMACOKINETICS

A rapid and fully-automated method for the quantitation of tricyclic antidepressants in serum using turbulent-flow liquid chromatography–tandem mass spectrometry

(2010) Autumn R. Breaud et al.   CLINICA CHIMICA ACTA

Imatinib dose escalation in two patients with chronic myeloid leukemia, with low trough imatinib plasma levels measured at various intervals from the beginning of therapy and with suboptimal treatment response, leads to the achievement of higher plasma levels and major molecular response

(2010) Edgar Faber et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry

(2010) R. Honeywell et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Who is in charge of assessing therapeutic drug monitoring? The case of imatinib

(2010) Thierry Buclin et al.   LANCET ONCOLOGY

Clinical pharmacokinetics of tyrosine kinase inhibitors

(2009) Nielka P. van Erp et al.   CANCER TREATMENT REVIEWS

Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasma

(2009) Benoit Blanchet et al.   CLINICA CHIMICA ACTA

Development of a high-performance liquid chromatographic–mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib

(2009) Sandra Roche et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry

(2009) A. Haouala et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability

(2008) N Widmer et al.   BRITISH JOURNAL OF CANCER

Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases

(2008) P MEDINA et al.   CLINICAL THERAPEUTICS